Abstract 376P
Background
This study aimed to explore the beneficial of intensive nutrition intervention with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods
174 locally advanced nasopharyngeal carcinoma patients (LANPC) receiving radical radiotherapy and concurrent cisplatin-based chemotherapy were enrolled from December, 2000 to December, 2016. Patients were divided into two groups as NI group（which received intensive, individualized nutrition education counseling and oral supplements if required), and UC group (general advice and nutrition booklet, without nutrition education). Propensity score matching was performed to balance the baseline differences between the two groups.
Results
Following one-to-one propensity score matching, survival outcomes for the matched data set indicated that the NI group achieved higher overall survival and failure-free survival (P<0.05) compared with UC. Subgroup analysis revealed that NI was associated with significantly improved OS (Hazard ratio [HR] =1.577, 95% Confidence interval [CI] = 1.055–2.357, P < 0.05) and FFS (HR = 1.53, 95% CI = 1.022–2.29, P<0.05). Additionally, the differences of the main adverse reactions after treatment between the two group were not statistically significant (P>0.05).
Conclusions
Early and intensive NI promoted beneficial outcomes in ameliorating the prognosis in loco-regionally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract